Active Biotech AB Interim Report January – March 2011

Apr 28, 2011 08:30 (CEST) 
* Laquinimod - complete results from Allegro Phase III trial presented
  * TASQ - Active Biotech and Ipsen enter into a broad partnership for the co-
    development and commercialization of TASQ in uro-oncology
  * ANYARA - ongoing Phase III study expected to be concluded in 2012
  * 57-57 - orphan drug status granted
  * ISI - project proceeding according to plan
  * RhuDex(TM) - preparations for continued clinical development in progress
  * Net sales SEK 2.7 M (2.8)
  * Operating loss SEK 70.9 M (loss: 51.0)
  * Loss after tax SEK 69.3 (loss: 53.5)
  * Loss per share for the period amounted to 1.02 (loss: 0.83)
  * Private placement of SEK 375 M completed

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel. +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available atwww.activebiotech.com




Active Biotech AB Interim Report January - March 2011:
http://hugin.info/1002/R/1509816/444684pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1509816]